I note that John Clark's comments (my highlight)...
"We are delighted to welcome Sergio Duchini to the PharmAust Board. Sergio’s extensive experience in strategy, governance, and capital access will be invaluable as we advance our clinical programs and strive to bring innovative therapies to market. His leadership will be crucial as we embark on our pivotal Phase 2/3 clinical study for monepantel."
Perhaps... capital access - is significant at this time, as we head into Phase2/3
DYOR and all that.
Ann: PharmAust appoints Sergio Duchini as Non-Executive Chairman, page-2
-
- There are more pages in this discussion • 57 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
-0.020(8.89%) |
Mkt cap ! $81.16M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 21.0¢ | 19.5¢ | $331.9K | 1.617M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 440882 | 20.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 12736 | 3 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| PAA (ASX) Chart |